Biogen and Samsung Bioepis' Byooviz launches in USA

3 June 2022

US biotech Biogen (Nasdaq: BIIB) and South Korea’s Samsung Bioepis have announced that Byooviz (ranibizumab-nuna), a biosimilar referencing Lucentis (ranibizumab) has been launched in the USA.

Healthcare provider engagement, promotional activity, collaborations with professional societies and patient advocacy groups have commenced and Byooviz will be commercially available on July 1, 2022, through major distributors across the USA. The list price will be $1,130 per single use vial to administer 0.5mg via intravitreal injection, which the companies say is 40% lower than the current list price of Lucentis, which is marketed in the USA by Roche (ROG: SIX).

The US Food and Drug Administration FDA approved Byooviz in September 2021 for the treatment of neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion, and myopic choroidal neovascularization.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK